Takeda, Cell Genesys Halt Phase III Trial Of Cancer Vaccine
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Cell Genesys and Japanese partner Takeda Pharmaceutical have stopped a Phase III trial of GVAX, a vaccine they co-developed to prevent prostate cancer. Cell Genesys acted after deaths of trial participants given GVAX exceeded by 20 the number of those on a placebo. The company said it had not identified the cause of the deaths. A spokesman said the firm was reviewing the matter with Takeda and considering a possible change in the business operations between the two partners. (Click here for more
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.